Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC)
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Aug 2024 Results published in the Oncologist
- 05 Jun 2024 Planned End Date changed from 30 Nov 2024 to 30 Dec 2024.
- 20 Jan 2024 Primary endpoint has been met. (Percentage of Participants with Progression-free Survival at 6 Months), as per Results presented at the 2024 Gastrointestinal Cancers Symposium